Weight Management

The expanded indication is supported by findings from the phase 3 TRANSCEND clinical trial.

FDA fast-tracks higher-dose weekly semaglutide, showing up to 20.7% weight loss.

Stopping weight management medications drives rapid weight regain and metabolic rebound—making long-term treatment key to optimal outcomes.

Mass-produced compounded GLP-1 drugs bypass FDA safeguards, raising sterility, quality, and supply-chain risks—putting patients at risk despite ending shortages.

Phase 2 trial finds combination therapy resulted in 22% body weight reduction at 72 weeks, with 92% of weight loss attributable to fat mass, addressing concerns about muscle loss with GLP-1 receptor agonists.

Michael Snyder, MD, of FuturHealth breaks down the patient safety risks of compounded glucagon-like peptide-1 (GLP-1) products and why structured care is essential as demand for these medications continues to surge.

FDA approves once-daily oral Wegovy for weight loss and long-term maintenance, matching injectable results while cutting cardiovascular event risk.

FDA clears oral Wegovy pills for weight loss, while Lemme Burn Gummies tout metabolic support; plus new thalassemia anemia drug and Lucentis biosimilar.

A multicohort analysis reveals that obesity substantially increases hospitalization and mortality risk across diverse infectious diseases.

WADA tracks GLP-1s like Ozempic, Wegovy, and Zepbound at the Olympics as pharmacists weigh muscle-loss risks and sports pharmacy guidance.

The FDA targets mass-marketed compounded GLP-1 drugs, warning of safety risks and deceptive ads as enforcement ramps up for weight-loss injectables.

Learn how pharmacists cut GLP-1 costs, streamline prior authorizations, guide safe switches, and bust social media myths for lasting adherence.

The scientific statement underscores obesity as a complex, socially driven condition and positions pharmacists as key partners in reducing stigma, improving access to care, and supporting equitable weight management.

Treatment with semaglutide offers benefits beyond solely cardiovascular risk reduction, lowering the risk of hospitalization across a range of comorbidities.

Research data show that weight regain after discontinuation of GLP-1 or GLP-1/GIP agonists is a significant risk.

David Shusterman, MD, reveals how reducing alcohol enhances GLP-1 therapy, improving insulin regulation, kidney health, and overall metabolic outcomes.

The American Heart Association (AHA) has released new guidance highlighting numerous obstacles that individuals with obesity face when treating and managing their condition, including limited access to healthy foods and weight stigma.

The FDA approved oral semaglutide to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D).

The glucagon-like peptide-1 (GLP-1) receptor agonist medications evaluated included semaglutide, tirzepatide, and liraglutide.

A tour through GLP-1’s unexpected biology.

Explore the differences between oral and injectable semaglutide for weight management, focusing on adherence, adverse effects, and patient preferences.

The pivotal clinical trial supports the concomitant administration of tirzepatide and ixekizumab, which significantly improves outcomes for patients with psoriatic arthritis (PsA) and obesity.

Recent studies reveal that weight recovery in anorexia nervosa does not ensure muscle restoration, highlighting the need for comprehensive recovery strategies.

New oral GLP-1 agonist orforglipron cuts A1C and drives meaningful weight loss in trials, offering easier dosing than injections.